Aura Biosciences Inc
NASDAQ:AURA

Watchlist Manager
Aura Biosciences Inc Logo
Aura Biosciences Inc
NASDAQ:AURA
Watchlist
Price: 8.95 USD -0.89% Market Closed
Market Cap: 444m USD
Have any thoughts about
Aura Biosciences Inc?
Write Note

Aura Biosciences Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aura Biosciences Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Aura Biosciences Inc
NASDAQ:AURA
Income from Continuing Operations
-$76.4m
CAGR 3-Years
-51%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$113m
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-36%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Aura Biosciences Inc
Glance View

Market Cap
445.5m USD
Industry
Biotechnology

Aura Biosciences, Inc. is a clinical-stage oncology company. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2021-10-29. The firm operates a platform, which focuses on ocular and urologic oncology. Its platform enables targeting of a range of solid tumors using Virus-Like Particles (VLPs) that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDCs). The firm's VDC platform offers a range of portfolio of targeted oncology therapeutics. The company engaged in developing AU-011 for the treatment of early-stage disease, which includes small melanomas and indeterminate lesions. Its product candidate, AU-011 consists of a human papilloma virus (HPV)-derived VLP conjugated to thousands of infrared laser-activated molecules. VDC prevents the conjugation from interfering with tumor binding enabling its selectivity to specifically modified HSPGs on tumor cells but not to normal cells. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer (NMIBC).

AURA Intrinsic Value
4.56 USD
Overvaluation 49%
Intrinsic Value
Price

See Also

What is Aura Biosciences Inc's Income from Continuing Operations?
Income from Continuing Operations
-76.4m USD

Based on the financial report for Dec 31, 2023, Aura Biosciences Inc's Income from Continuing Operations amounts to -76.4m USD.

What is Aura Biosciences Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-51%

Over the last year, the Income from Continuing Operations growth was -30%. The average annual Income from Continuing Operations growth rates for Aura Biosciences Inc have been -51% over the past three years .

Back to Top